Abstract
Since healthcare resources are scarce, choices have to be made on how they will be allocated. The use of economic evaluations using cost-effectiveness analyses has increased rapidly as policymakers have realized their value in maximizing the population's benefits (in terms of length of life and health status) within a given budget. Following efforts by OMERACT to create reference case definitions for the conduct of economic evaluation in rheumatoid arthritis, osteoporosis, and osteoarthritis, we review various methodological areas and research decisions that could benefit from a consensus between researchers, clinicians, and drug developers in terms of an ankylosing spondylitis (AS) reference case. Ten methodological issues are presented that will be important for future development of evaluations. Tentative proposals to define the issues in a reference case for AS are made, along with recommendations for further research.
| Original language | English |
|---|---|
| Pages (from-to) | 1178-1183 |
| Number of pages | 6 |
| Journal | The Journal of Rheumatology |
| Volume | 34 |
| Issue number | 5 |
| Publication status | Published - May 2007 |
Keywords
- ankylosing spondylitis
- economics
- cost effectiveness
- ANTI-TNF THERAPY
- ANTITUMOR NECROSIS FACTOR
- DISEASE-ACTIVITY INDEX
- COST EFFICACY ANALYSIS
- QUALITY-OF-LIFE
- RHEUMATOID-ARTHRITIS
- TECHNOLOGY-ASSESSMENT
- SENSITIVITY-ANALYSIS
- CONTROLLED TRIAL
- INFLIXIMAB